Precigen, Inc. announces a non-dilutive financing agreement with investment funds managed by Pharmakon Advisors, LP.
The agreement provides Precigen with up to $125 million, with an initial tranche of $100 million funded at closing.
This financing will fortify Precigen's balance sheet and support the U.S. commercialization of PAPZIMEOS, potential international market expansion, and pursuit of pediatric and other HPV-related indications.
Credit Facility Agreement
Precigen secured a credit facility agreement with up to $125 million, enhancing financial flexibility for growth and commercialization.
Strategic Partner
Collaboration with Pharmakon Advisors, LP, a leading investor in non-dilutive debt for life sciences, showcases strategic funding support.
Financial Flexibility and Growth
The funding strengthens Precigen's balance sheet, enabling robust U.S. commercialization of PAPZIMEOS and future expansion plans.
- The financing agreement ensures Precigen's ability to advance commercialization efforts for PAPZIMEOS, a novel immunotherapy treatment.
- It also highlights the company's strategic approach towards international market expansion and diversification into additional HPV-related indications.
With this non-dilutive financing agreement, Precigen, Inc. is well-positioned to drive significant growth, commercialize innovative treatments, and solidify its presence as a leading biopharmaceutical innovator.